Compare SCSC & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SCSC | COLL |
|---|---|---|
| Founded | 1992 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1997 | 2015 |
| Metric | SCSC | COLL |
|---|---|---|
| Price | $58.03 | $22.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $43.00 | ★ $51.40 |
| AVG Volume (30 Days) | 288.3K | ★ 837.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.33 | N/A |
| EPS | ★ 3.64 | N/A |
| Revenue | ★ $3,846,260,000.00 | $780,567,000.00 |
| Revenue This Year | $2.60 | $8.01 |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $15.65 | ★ N/A |
| Revenue Growth | 7.79 | ★ 23.62 |
| 52 Week Low | $33.76 | $23.11 |
| 52 Week High | $66.78 | $50.79 |
| Indicator | SCSC | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 48.84 | 22.88 |
| Support Level | $49.77 | N/A |
| Resistance Level | $59.46 | $35.89 |
| Average True Range (ATR) | 1.98 | 1.00 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 32.97 | 3.44 |
ScanSource Inc is a technology distributor uniquely positioned to address complex, converging technologies and to accelerate growth for channel sales partners across hardware, SaaS, connectivity, and cloud. The Company provides technology solutions and services from suppliers of mobility and barcode, POS, payment terminals, physical security, networking, communications, connectivity, and cloud services to channel sales partners located mainly in the United States and Brazil. It has two reportable segments based on the sales model: Specialty Technology Solutions, which generates maximum revenue and includes hardware, SaaS, and subscription services through a wholesale/resale sales model, and Intelisys & Advisory. Geographically, it derives the majority of its revenue from the United States.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.